The Centers for Medicare and Medicaid Services could authorize lower-cost generic versions of Astellas Pharma US Inc. and Pfizer Inc.’s prostate cancer drug Xtandi in government-sponsored insurance programs using existing federal government licensing and patent rights that are separate from march-in rights, a trio of advocacy organizations argued in a 9 April letter.
Key Takeaways
-
Now that a march-in request for Xtandi has failed again, advocates are pushing alternatives that could accelerate the launch of generic enzalutamide in federal programs.
-
Twenty years ago, one of the provisions was used by the George W. Bush Administration to secure a 50% reduction in the price of Bayer's Cipro as a safeguard against anthrax attacks
The request by Knowledge Ecology International, Universities Allied for Essential Medicines and the Union for Affordable Cancer Treatment is the latest development in an eight-year, so far unsuccessful, campaign by the groups and others to leverage patent
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
